Body height, serum calcium, hip circumference, and serum 25(OH)D in relation to homozygote phenotypes in the females and males.

<p>The Tromsø study.</p><p>^† P < 0.05 vs 1s/1s and 2/2;</p><p>^†† P < 0.01 vs 1s/1s and 1f/1f;</p><p>^††† P < 0.05 vs 1f/1f;</p><p>^†††† P < 0.01 vs 1f/1F and 2/2 (ANOVA with Bonferroni correction for multiple analyses). Data are number (%) or mean ± SD</p><p>* Analysed in 1316 females;</p><p>** analysed in 1797 non-smoking females;</p><p>*** analysed in 1302 males;</p><p>****analysed in 1342 non-smoking males</p><p>Body height, serum calcium, hip circumference, and serum 25(OH)D in relation to homozygote phenotypes in the females and males.</p

Characteristics of the 11 704 subjects in relation to DBP phenotypes.

<p>The Tromsø study.</p><p>^† P < 0.01 vs 1s/1s;</p><p>^†† P < 0.05 vs 1f/1f and 2/2;</p><p>^††† P <0.05 vs 2/2;</p><p>^†††† P < 0.001 vs 1s/1s and 1f/1f; (ANOVA with Bonferroni correction for multiple analyses); Data are number (%) or mean ± SD</p><p>*Analysed in 10337 subjects not using BP medication;</p><p>**analysed in 6342 subjects;</p><p>***analysed in 6702 subjects;</p><p>****analysed in 3304 subjects;</p><p>‡ analysed in 4501 non-smoking subjects;</p><p>Characteristics of the 11 704 subjects in relation to DBP phenotypes.</p

Number of incident endpoints (MI, T2DM, total cancer and death and types of cancer) after Tromsø 4 in 1994 (those with their first endpoint before Tromsø 4 excluded) in relation to DBP phenotype.

<p>The Tromsø study.</p><p>* P < 0.05 vs 1s/1s and 2/2, Chi-square test</p><p>Number of incident endpoints (MI, T2DM, total cancer and death and types of cancer) after Tromsø 4 in 1994 (those with their first endpoint before Tromsø 4 excluded) in relation to DBP phenotype.</p

Gender adjusted Cox hazard ratios and 95% confidence intervals for incident cancer (all locations) according to DBP phenotype groups.

<p>The Tromsø study.</p><p>Gender adjusted Cox hazard ratios and 95% confidence intervals for incident cancer (all locations) according to DBP phenotype groups.</p

Number of subjects with specific endpoints and number of subjects in corresponding control groups and hazard ratio with 95% confidence interval in relation to genotype score quartile and genotypes in the four selected SNPs.

<p>Cox regression with adjustment for age, gender, BMI and vitamin D/cod liver oil supplementation. None of the relations for the individual SNPs remained statistically significant after correction for multiple comparisons with a factor of 32.</p>*<p>Quartile with highest serum 25(OH)D level.</p>†<p>Risk allele.</p

Genotype frequency and serum 25(OH)D levels in relation to genotype in the entire cohort.

*<p>Analyzed in the entire cohort of 9471 subjects;</p>**<p>analysed in 4567 subjects;</p>***<p>P, linear trend across genotypes with gender, age, BMI, vitamin D/cod liver oil supplementation and season as covariates.</p

Characteristics of the study population in 1994–1995.

*<p>Measured only in those attending the second visit of the Tromsø study 1994–1995.</p

Number of subjects with specific types of cancer and number of subjects in corresponding control groups and hazard ratio with 95% confidence interval in relation to genotype score quartile and genotypes in the four selected SNPs.

*<p>P<0.05; Cox regression with adjustment for age, gender, BMI and vitamin D/cod liver oil supplementation. Correction for multiple comparisons for the individual SNPs was performed with a factor of 32.</p>**<p>Quartile with highest serum 25(OH)D level.</p>†<p>Risk allele.</p

Summary characteristics of meta-analyses and the individual RCTs included in MA on non-skeletal effects of vitamin D supplementation.

<p>Summary characteristics of meta-analyses and the individual RCTs included in MA on non-skeletal effects of vitamin D supplementation.</p

PRISMA flow diagram.

<p>PRISMA flow diagram.</p